- Home
- SYRE vs CLDX Comparison
SYRE vs CLDX Comparison
Compare SYRE & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- CLDX
- Stock Information
- Founded
- SYRE 2013
- CLDX N/A
- Country
- SYRE United States
- CLDX United States
- Employees
- SYRE N/A
- CLDX N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SYRE Health Care
- CLDX Health Care
- Exchange
- SYRE Nasdaq
- CLDX Nasdaq
- Market Cap
- SYRE 1.2B
- CLDX 1.3B
- IPO Year
- SYRE 2016
- CLDX 2008
- Fundamental
- Price
- SYRE $16.14
- CLDX $18.15
- Analyst Decision
- SYRE Strong Buy
- CLDX Buy
- Analyst Count
- SYRE 8
- CLDX 8
- Target Price
- SYRE $51.50
- CLDX $54.29
- AVG Volume (30 Days)
- SYRE 661.8K
- CLDX 749.8K
- Earning Date
- SYRE 05-08-2025
- CLDX 05-05-2025
- Dividend Yield
- SYRE N/A
- CLDX N/A
- EPS Growth
- SYRE N/A
- CLDX N/A
- EPS
- SYRE N/A
- CLDX N/A
- Revenue
- SYRE N/A
- CLDX $7,020,000.00
- Revenue This Year
- SYRE N/A
- CLDX N/A
- Revenue Next Year
- SYRE N/A
- CLDX $27.01
- P/E Ratio
- SYRE N/A
- CLDX N/A
- Revenue Growth
- SYRE N/A
- CLDX 1.99
- 52 Week Low
- SYRE $16.13
- CLDX $17.63
- 52 Week High
- SYRE $40.84
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- SYRE 35.24
- CLDX 34.76
- Support Level
- SYRE $16.71
- CLDX $19.48
- Resistance Level
- SYRE $18.28
- CLDX $20.38
- Average True Range (ATR)
- SYRE 1.21
- CLDX 1.04
- MACD
- SYRE -0.03
- CLDX -0.02
- Stochastic Oscillator
- SYRE 0.15
- CLDX 12.32
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.